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Treatment of chronic hepatitis B virus (HBV) infection is highly effective in suppressing
viral replication, but complete cure is rarely achieved. In recent years, substantial
progress has been made in the development of immunotherapy to treat cancer. Applying
these therapies to improve the management of chronic HBV infection is now being
attempted, and has become an area of active research. Immunotherapy with vaccines
and checkpoint inhibitors can boost T cell functions in vitro, and therefore may be
used to reinvigorate the impaired HBV-specific T cell response. However, whether
these approaches will suffice and restore antiviral T cell immunity to induce long-term
HBV control remains an open question. Recent efforts have begun to describe the
phenotype and function of HBV-specific T cells on the single epitope level. An improved
understanding of differing T cell specificities and their contribution to HBV control will
be instrumental for advancement of the field. In this review, we outline correlates of
successful versus inadequate T cell responses to HBV, and discuss the rationale behind
therapeutic vaccines and checkpoint inhibitors for the treatment of chronic HBV infection.
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INTRODUCTION
Hepatitis B virus (HBV) infection is an immense burden to global health. Despite the availability of
an effective prophylactic vaccine over 250 million individuals are chronically infected (1). Chronic
infection contributes to the development of fibrosis, cirrhosis, and hepatocellular carcinoma,
leading to an estimated 887,000 deaths annually (1, 2). Most patients require lifelong nucleos(t)ide
analogue (NA) treatment since therapy is not curative, and merely suppresses viral replication.
However, NA treatment is highly effective, reduces liver inflammation and has a good safety profile.
Still, treatment does not eliminate the risk of hepatocellular carcinoma; and withdrawal from
treatment can cause viral relapse and severe inflammation of the liver. Long-term therapy also
rarely leads to a functional cure of a chronic infection, as defined by the clearance of the serum
hepatitis B surface antigen (HBsAg) and an undetectable viral load in serum. Thus, there is an
urgent need to develop new and more effective therapeutics.
HBV is a small enveloped DNA virus belonging to the family Hepadnaviridae. The virus has
a distinct tropism for hepatocytes in which it generates a covalently closed circular (ccc) DNA
template to produce new virions, and is able to integrate into the host genome (Figure 1) (3).
The persistence of the viral genome represents a major obstacle preventing a sterilizing cure of
a chronic HBV infection. It remains unclear if, and how, this transcriptional template can be
completely eliminated from all hepatocytes. In addition, transcription of HBV DNA, either from
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cccDNA or from integrated HBV DNA leads to the secretion
of high quantities of viral antigen, predominantly HBsAg
(Figure 1) (4), which is thought to hinder effective antiviral
immune responses. Nevertheless, permanent containment
of HBV replication can be achieved, as HBsAg clearance
infrequently occurs following a chronic infection, and is
readily observed following acute infection in adults. Central
to viral resolution are HBV-specific T cells, that become
impaired during chronic infection (5). Restoration of T cell
immunity through immunomodulation has become a field
of active investigation, with several immunomodulatory
strategies being explored in preclinical and clinical studies.
The ultimate goal of HBV immunotherapy is to induce a
sustained loss of HBsAg transcription while cccDNA persists
within hepatocytes. This state mirrors that what is observed
in adults following acute HBV infection (6). Loss of HBsAg
will not only allow chronic patients to discontinue therapy,
it is also associated with lower hepatocellular carcinoma risk,
especially if HBs seroconversion occurs before the age of
50 (7, 8).
HBV immunotherapy aims to suppress HBV replication
long-term by reinvigorating the host immune response.
Immunotherapy can target innate and adaptive immunity.
Innate strategies include those that activate pattern recognition
FIGURE 1 | Schematic representation of a chronic HBV-infected liver. HBV persists as covalently closed circular (ccc)DNA in the nucleus of hepatocytes, and
integrates into the host genome. Integrated and episomal HBV DNA contribute to ongoing viral antigen secretion, in particular HBsAg. HBV-specific T cells target
hepatocytes infected with HBV through the secretion of cytokines and cytolytic molecules. Core and polymerase-specific T cells are functionally distinct.
Envelope-specific T cells are typically absent during chronic HBV infection, and with the pre-existing quantities of HBsAg, these cells may be a less suited target to
boost by immunotherapy. Aspects that need to be considered in the design and monitoring of HBV immunotherapy are listed.
receptors, such as toll-like receptors and retinoic acid-inducible
gene I (RIG-I), rely on cytokines directed at HBV-infected
hepatocytes or activate NK cells. Adaptive strategies consist of
therapies that restore T cells and antibodies, including T cell
receptor (TCR) redirected T cells, chimeric antigen receptor
(CAR) T cells and bi-specific soluble TCRs; checkpoint inhibitors
and therapeutic vaccines. In this review we specifically focus on
checkpoint inhibitors and therapeutic vaccines since they are
capable of enhancing both T cell and B cell immunity. However,
also other strategies are being explored, such as the reduction of
HBsAg secretion from infected hepatocytes by blocking mRNA
transcription by using small interfering RNA (siRNA) that knock
down the expression of specific viral transcripts (9, 10).
Experimental data in the chronic lymphocytic
choriomeningitis virus (LCMV) mouse model has demonstrated
that checkpoint inhibitors and therapeutic vaccines can, to
some extent, boost antiviral immunity (11, 12). Whether similar
approaches will be sufficient to achieve a functional cure of a
chronic HBV infection remains to be seen. In the coming years
these strategies will be evaluated in order to determine their
safety, efficacy, and optimal dosing. In this context, identifying
the patients in which the immune system is amendable to these
therapies will be essential. An improved understanding of the
immunological mechanisms associated with control of HBV
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replication will be instrumental for design, and monitoring of
these interventions.
Herein, we outline our current understanding of HBV
control as can be observed in individuals following an acute
or chronic resolving infection with a specific focus on T
cells. Furthermore, we provide an overview of the mechanisms
and characteristics of HBV-specific T cell exhaustion, and
we examine the degree of T cell restoration that can be
observed with current therapies. These paragraphs will serve as
a framework to discuss the rationale behind immune checkpoint
modulation and therapeutic vaccines for the treatment of chronic
HBV infection.
PROTECTIVE IMMUNITY FOLLOWING AN
ACUTE OR CHRONIC RESOLVING HBV
INFECTION
HBV infection is self-limiting in over 95% of infected adults.
Only a small subset of patients progresses to a chronic stage,
and this occurs more often in those patients who are immune
compromised (13). The majority of chronic HBV patients are,
however, infected early in life, as a newborn or a child. Factors
that determine the outcome of infection remain largely undefined
but certain human leukocyte antigens (HLA), such as HLA-
DPA1 and DPA2 have been associated with an increased risk of a
chronic HBV infection (14–16).
There is strong evidence that HBV-specific T cells are required
for viral resolution. This is supported by chimpanzee studies in
which CD4 or CD8T cell depletion resulted in failure to control
acute HBV infection (17, 18). Furthermore, acute resolving
HBV infection is characterized by robust, highly functional T
cells directed against all viral proteins. Viral resolution already
becomes apparent during the incubation phase as HBV DNA
levels start declining even before the onset of symptoms and
liver damage (19–21). Clinically, viral resolution is defined as
HBs seroconversion and undetectable HBV DNA in serum,
which generally occurs within the first 24 weeks post infection.
After HBs seroconversion, the frequency of the HBV-specific
T cells declines and continues to do so until at least 40
weeks after the onset of symptoms (22). The residual memory
T cell response will persist for decades and provide effective
containment of HBV replication while the viral genome persists
as cccDNA within hepatocytes. The exact mechanisms of T cells
driving control of HBV replication are poorly defined, but they
are thought to primarily use noncytopathic effector functions
(Figure 1) (23, 24).
We and others have recently observed distinct T cell
functions depending on the targeted HBV epitope (22, 25,
26). For example, in early acute infection we observed that
HLA∗A2:01 core18-specific T cells were characterized by higher
expression of molecules, such as granzyme B and perforin, and
showed a stronger cytokine response (IFN-γ ) following peptide
stimulation compared to polymerase455-specific T cells from the
same individual (22). These findings were accompanied by a
distinct T cell phenotype ex vivo. Core18-specific T cells showed
a stronger expression of T cell activation markers (CD38 and
PD-1), had increased levels of the T-box transcription factor T-
bet when compared to polymerase455-specific T cells (27–29).
Most HBV-specific T cells were classified as effector memory
cells, but polymerase455-specific T cells had higher frequencies
of effector memory T cells re-expressing CD45RA (TEMRA).
These findings suggest a distinct regulation and contribution of
epitope-specific T cells to viral control.
Most of our understanding of HBV control is defined in
adult acute resolving infection. How these findings translate to
chronic patients who clear HBsAg is yet to be determined. These
subjects are difficult to study as the estimates of HBsAg clearance
rates for NA therapy are around two percent with no differences
between HBeAg positive or negative patients [reviewed in (30)].
Additional studies are still needed to determine if HBsAg
clearance rates vary among different patient populations and
HBV genotypes (31). Recently, a protective effect of core and
polymerase-specific T cells against hepatic flares when patients
are taken off therapy, was reported (32). This could imply that
these specificities are an attractive target for immunotherapy, in
particular because these specificities are often detectable during
chronic infection (22, 25, 33).
T CELL EXHAUSTION DURING CHRONIC
HBV INFECTION
In chronic infection, HBV-specific T cells gradually become
dysfunctional, and lose their ability to proliferate, produce
cytokines, and exert cytotoxicity toward infected cells. This
phenomenon, also known as T cell exhaustion, was first described
in mice chronically infected with LCMV (34, 35). T cell
exhaustion is characterized by a sustained overexpression of
multiple inhibitory molecules. Ultimately, severely exhausted T
cells are lost through cell death. Chronic HBV-infected patients
display many of the hallmarks of T cell exhaustion. Indeed, the
frequency of HBV-specific T cells is diminished and evenmore so
in patients with a high viral load (36). The residual T cell response
is directed against a limited number of epitopes, primarily located
in the core and polymerase proteins, with few responses directed
against the envelope and X proteins (25, 33, 37, 38).
Preserved HBV-specific T cells selectively over express several
inhibitory molecules, of these PD-1 has been best-characterized
(29, 38, 39). Other inhibitory receptors such as LAG-3, TIM-
3, and CTLA-4 have not been studied as extensively. Some
of these markers are difficult to study because they are
often insignificantly expressed on HBV-specific CD8T cells in
peripheral blood (40), but can more easily be detected on T
cells within the liver (41). Intrahepatic virus-specific T cells often
display a more profound exhausted phenotype, reflected by a lack
of the memory marker CD127 and a stronger co-expression of
inhibitory receptors, such as PD-1 and TIM-3 (36, 39, 41, 42). The
exhausted phenotype of HBV-specific T cells is equally paralleled
by functional defects with a reduced cytotoxic, proliferative,
and mitochondrial function (36, 38, 43–46). Interestingly, it
was found that the function of exhausted HBV-specific CD8T
cells could partially be restored by correcting mitochondrial
dysfunction using mitochondria-targeted anti-oxidants (43).
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HBV-specific T cell exhaustion is principally maintained
by the continued exposure to HBV antigens. PD-1 ligands,
suppressive cytokines such as IL-10 and TGF-ß (47–51), impaired
function of dendritic cells (DC), natural killer (NK) cells,
and increased frequencies of regulatory T cells and myeloid-
derived suppressor cells (MDSC), have all been suggested
to negatively impact HBV-specific T cell immunity (52–61).
The virus can also escape immune pressure through viral
escape mutants. HBV has a relatively low mutation rate and
because the open reading frames of the viral genome partially
overlap, there are constraints to the number of amino acid
substitutions that are viable. Nonetheless, genetic diversity
consistent with immune pressure is observed during chronic
infection: mainly within the core and envelope protein, but
also to a lesser degree in the polymerase protein (62–64). In
sum, there are multiple mechanisms contributing to T cell
dysfunction during chronic HBV infection. This indicates that
modulating a single pathwaymay not sufficiently restore antiviral
T cell immunity to attain a functional cure of a chronic
HBV infection.
T CELL RECOVERY WITH CURRENT
TREATMENT REGIMENS
Chronic HBV infection is a highly heterogenous disease
characterized by varying levels of viral replication and liver
damage. Clinically this has led to the categorization of patients
into four clinical phases, based on varying serum levels of
HBV DNA, HBeAg, and alanine aminotransferase (ALT). NA
treatment is generally only administered in those phases with
elevated serum ALT levels, that indicate liver damage resulting
from immune-mediated lysis of hepatocytes (65). These phases
are best known as immune tolerant (HBeAg positive infection),
immune active (HBeAg positive hepatitis), inactive carrier
(HBeAg negative infection), and HBeAg-negative hepatitis (65).
NA treatment is highly effective in almost all chronic HBV
patients leading to an undetectable serum HBV DNA. With
respect to T cells, effective NA treatment in HBeAg positive
chronic patients has repeatedly been associated with a partial
and transient recovery of HBV-specific T cells, with increased
proliferation and function in vitro (66–68). Recovery of T cell
function has been observed as early as two weeks after start of NA
therapy (66, 67), but wanes off after approximately six months
of treatment (68). Prolonged NA treatment of HBeAg negative
patients also leads to a partial, but more long-lasting, recovery
of T cells (69). The partial recovery of T cell function following
NA therapy is to some extent remarkable because, although
HBV DNA becomes undetectable, these agents generally do not
lower serum HBsAg levels (70). The persistence of HBsAg may
explain why these HBV-specific T cells remain less functional
when compared to patients who clear HBsAg following an
acute or chronic infection (69, 71, 72). This suggests that only
long-term successful suppression of both HBV replication and
antigen production will allow for a more profound recovery
of T cell function. On the other hand, studies in the LCMV
mouse model and chronic HCV infection indicate that virus-
specific T cells remain exhausted, even following the complete
eradication of antigen, because of an irreversible epigenetic
state (73–76). Therefore, HBV antigen removal should likely
be supported by additional immune modulation to achieve a
functional cure.
IMMUNE CHECKPOINT BLOCKADE TO
BOOST HBV-SPECIFIC T CELLS
HBV-specific T cells are required for long-term HBV control,
but become functionally defective, and greatly reduced in their
frequency during chronic infection. Nevertheless, functionally
impaired T cells are maintained, making them a potential target
for immunotherapeutic intervention. One approach to boost
HBV-specific T cells is to prevent the interaction of inhibitory
receptors on their cell surface with their ligands. Studies in the
chronic LCMVmouse, HBV mouse, and woodchuck model have
demonstrated that immune checkpoint blockade can reinvigorate
T cell function (11, 77, 78). Similarly, blocking PD-1 (28, 36,
38, 39, 41), CTLA-4 (43), TIM-3 (40, 42), and 2B4 (44) have
previously been described to boost HBV-specific T cells in vitro
(Figure 2). Of these receptors, PD-1 is often the dominant
responsive receptor when blocked in vitro (39). Checkpoint
blockade mainly improves T cell proliferation, and to a lesser
degree T cell function. Not all HBV-specific T cells are equally
susceptible to checkpoint blockade. Effector memory HBV-
specific CD8T cells from peripheral blood are most responsive
to PD-1 blockade, similar to what has been observed for chronic
HCV andHIV-infection (39, 79, 80). Intrahepatic virus-specific T
cells are oftenmore exhausted than their peripheral counterparts,
and therefore benefit from the blockade of additional inhibitory
receptors (36, 81). At present, the number of clinical trials
evaluating checkpoint blockade in chronic HBV infection are still
limited. One of these studies was performed to assess efficacy
in a phase 1/2 clinical trial to treat hepatocellular carcinoma,
with some patients being infected with HBV, but T cell function
was not assessed (82). In another study a group of HBeAg-
negative chronic HBV patients received a single low-dose of
nivolumab to block the PD-1 pathway (83). This study reported
one out of fourteen patients achieving a functional cure, with
most patients having a minimal decline of HBsAg. Core and
envelope-specific T cells were analyzed by fluorospot, but T cell
responses did not change in frequency over time. Both studies
included virally suppressed chronic HBV patients so any effect
on HBV DNA could not be detected. PD-1 blockade is generally
well tolerated at a low dose, but additional dosage studies will
be clearly needed to further assess their efficacy and safety since
only a few small studies have been conducted. Higher dosages, or
combination therapy, could permit a more pronounced recovery
of T cells, but simultaneously increases the risk of adverse
events, such as autoimmune diseases and hepatic flares (84–86).
Further development of checkpoint inhibitors as standard care
for chronic HBV infection should clearly take into account their
safety profile, since current NA treatment has virtually no side
effects and low cost.
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FIGURE 2 | Immunotherapeutic options to reinvigorate defective HBV-specific T cells. Therapeutic vaccines consist of, or express, HBV antigens. Processing of these
antigens by professional antigen presenting cells (APC) can prime new, and reactivate pre-existing, HBV-specific T cells (left panel). Immune checkpoint inhibitors:
monoclonal antibodies that prevent the interaction between programmed cell death protein-1 (PD-1) and its ligand, and boost the function of HBV-specific T cells
(right panel).
THERAPEUTIC VACCINES
In contrast to checkpoint inhibitors which reinvigorate the
function of pre-existing antiviral immunity, therapeutic vaccines
are designed to boost immunity by also priming new antiviral
responses (Figure 2). Therapeutic vaccines differ from preventive
vaccines in their mode of action and in their administration
during infection, instead of before infection. Therapeutic
vaccines rely on inducing effective CD4 and CD8T cell responses
and not as much on B cells and antibody responses. Moreover,
HBV vaccine antigens are preferably presented to the immune
system outside the liver allowing processing by professional
antigen presenting cells, such as dendritic cells (87). Overall,
there is substantial evidence from the LCMV and HBV mouse
models supporting the use of therapeutic vaccination for the
treatment of chronic viral infections (88, 89). Unfortunately,
many of these animal model-derived therapeutic HBV vaccines
have not been evaluated for their efficacy in humans, and
those that were typically showed limited efficacy (90–93). These
observations clearly stress the need to assess vaccine efficacy in
chronic HBV-infected patients. The HBsAg-based prophylactic
vaccine is highly effective in preventing the disease mainly by the
induction of neutralizing antibodies, while the vaccine failed to
induce HBsAg clearance in chronic HBV-infected patients (94–
96). These vaccines could have failed to induce a functional cure
because they were not potent enough to induce HBV-specific
T cells. Additionally, the limited effect of the HBsAg-based
prophylactic vaccine, when used in therapeutic strategies, can—
at least in part—be explained by the already high levels of
circulating HBsAg in chronic HBV patients (97). The observation
that therapeutic vaccination against LCMV is more effective
when it is administrated in mice with a low viral antigen load
may be in line with this (12). Such studies are rather difficult
to perform in humans as current NA treatment regimens do
not significantly lower HBsAg serum levels (70). More recent
studies have evaluated other and additional HBV antigens, such
as the core and polymerase protein, and optimized the mode of
antigen administration through recombinant antigen- or DNA
vaccination (90–92). To date, the majority of therapeutic vaccines
have had limited success in clinical trials and induced only a
partial restoration of T cells at best, without a durable effect
on HBsAg and HBV DNA. A list of previous and therapeutic
vaccines under development is provided elsewhere (98–100).
The limited efficacy of current therapeutic vaccines raises
the question whether they fail to rejuvenate pre-existing HBV-
specific T cells because of ongoing exposure to viral antigens.
Alternatively, the vaccine antigens may not sufficiently match
the patient’s HBV genotype. Given the lack of T cell recovery it
seems that these vaccines need to be given in combination with
other therapies. In order to enhance their efficacy, vaccination
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is currently being combined with checkpoint blockade, as these
inhibitory receptorsmay limit clonal expansion of T cells. Indeed,
a beneficial effect of PD-1 blockade on therapeutic vaccination is
observed in the LCMVmousemodel and in woodchucks infected
with HBV (101, 102). Moreover, HBV-specific T cells that were
induced by dendritic cells are more responsive to PD-1 blockade
when compared to those T cells primed by hepatocytes in HBV
replication-competent transgenic mice (103). These synergistic
effects did, however, not results into a clinical benefit in a
small pilot study that administered nivolumab and a therapeutic
vaccine to ten virally suppressed chronic HBV patients (83).
Ultimately, these vaccines need to sufficiently reinvigorate
antiviral immunity so that hepatocytes infected with HBV can
be cleared. This will require a sufficiently broad T cell repertoire
covering conserved regions of the virus, so that it can prevent
viral escape. One difficulty for the design of epitope-based
vaccines is the limited number of HBV class I and II epitopes
that have been identified. This is especially relevant as there is
a distinct global distribution of HLA alleles and HBV genotypes.
Yet the majority of class I epitopes available for human studies
are still HLA-A∗02 restricted and our understanding of genotypic
variation of HBV-specific T cell epitopes remains limited (104).
The inclusion of degenerate T cell epitopes, i.e., those that can be
presented on multiple HLA alleles, could be used to broaden the
vaccine efficacy for differing HLA populations. (105, 106).
IMMUNOTHERAPY IN DIFFERENT
PHASES OF CHRONIC INFECTION
Current guidelines recommend NA treatment for chronic
patients with active hepatitis and moderate to severe fibrosis.
The inflammatory events and impaired liver architecture of these
patients could however be less suited for immunotherapeutic
intervention, since they can directly hinder the function of HBV-
specific T cells and accessibility to infected hepatocytes (107,
108). In theory, immune tolerant patients could more likely
respond to immunotherapy as they have a more preserved liver
anatomy and HBV-specific T cells (109). In line with this notion
is a recent study that demonstrated that HBV-specific T cells
from 13 immune tolerant patients had a significant increase in
IFN-γ production in response to overlapping HBV-peptides after
the addition IL-2, while this increase could not be observed for
16 immune active patients. (103). Similarly, the fate of T cell
exhaustion may be more flexible if the exposure to HBV antigens
and other immune impairment mechanisms remains limited. It
must be noted that the treatment of immune tolerant patients is
still controversial and more detailed studies are needed to further
substantiate this hypothesis.
FUTURE PERSPECTIVES
There is extensive evidence indicating that T cells are required
for HBV control, but these responses become defective in chronic
patients. Immunotherapy aimed at reinvigorating dysfunctional
T cells represents a logical approach to induce a functional
cure of a chronic infection. Experimental studies can provide a
proof of concept, but their efficacy does not always translate into
chronic patients. For one, because in chronic patients multiple
T cell impairment mechanisms are operative over a period of
decades and some T cell defects may not be fully reversible.
Recent efforts have begun to better define HBV-specific T cell
phenotype and function in relation to their epitope-specificity.
Checkpoint inhibitors and therapeutic vaccines have thus far had
limited success in a small number of clinical trials, with most
studies reporting only a partial recovery of T cells. It must be
noted that the optimal drug dosages and the appropriate timing
of these treatments are yet to be determined. Additionally, the
lack of efficacy has been attributed to the high antigenic burden,
in particular of HBsAg, which cannot be overcome by current
standard of care HBV therapies. Combining immunomodulation
with novel direct-acting antivirals, that can inhibit both viral
replication and antigen load may be required to achieve a
functional cure. Supported by recent methodological advances
of platforms, such as multi-parameter flow cytometry and RNA-
sequencing of HBV-specific T cells from both blood and liver it
is expected to accelerate progress in the field at an unprecedented
level. It is with this increased understanding that we will be able
to develop safe and effective immunotherapies for HBV.
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